Serum anti-enteric neuronal antibodies in patients with achalasia and their association with clinical profiles

Table 4 Comparison of treatment outcomes between anti-enteric neuronal antibodies-positive and -negative patients with achalasia after overlap weighting, mean ± SD/median interquartile range

Outcomes	AENA negative (n = 18)	AENA positive (n = 23)	P value
1-month follow-up
Eckardt scores	0.00 (0.00 to 1.00)	1.00 (0.58 to 2.00)	0.031a
Δ Eckardt scores1	6.00 (5.00 to 7.31)	4.68 (4.00 to 6.48)	0.173
6-month follow-up
Eckardt scores	0.00 (0.00 to 1.00)	1.00 (1.00 to 2.00)	0.005b
Δ Eckardt scores1	5.51 (4.00 to 9.00)	5.00 (4.00 to 6.20)	0.233
CARS scores	1.00 (1.00 to 1.43)	1.00 (1.00 to 2.05)	0.915
Δ CARS scores1	2.89 (1.00 to 4.00)	2.98 (1.00 to 4.00)	0.939
Reflux esophagitis			0.497
None	68.9	64.1
Los Angeles-A	10.0	28.1
Los Angeles-B	10.9	2.8
Los Angeles-C	10.1	5.0
IRP, mmHg	1.99 (0.69 to 4.38)	2.36 (0.67 to 5.00)	0.840
Δ IRP, mmHg1	9.67 (-2.05 to 13.77)	13.40 (7.55 to 17.69)	0.359
Barium width, mm	25.10 (11.00 to 30.00)	22.84 (15.39 to 36.55)	0.674
Δ Barium width, mm1	16.82 (9.18 to 24.17)	19.29 (0.16 to 26.08)	0.574

^aP < 0.05.

^bP < 0.01.

¹Changes compared to these at baseline.

Statistical comparisons were performed using weighted Wilcoxon rank-sum tests for continuous variables and weighted χ² tests for categorical variables to account for overlap weights. AENA: Anti-enteric neuronal antibodies; CARS: Contents, anatomy, resistance, and stasis; IRP: Integrated relaxation pressure.